PAC-1 (VO-100)

This product is for research use only, not for human use. We do not sell to patients.

PAC-1 (VO-100)
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
250mg$450Check With Us
500mg$850Check With Us
1g$1275Check With Us

Cat #: V0025 CAS #: 315183-21-2 Purity ≥ 98%

Description: First procaspase-activating compound (PAC-1; VO 100) is a potent small-molecule activator of procaspase-3 that directly catalyzes the maturation of procaspase-3 to the active caspase-3 by inducing the cleavage of procaspase-3 in a time-dependent manner.

References: Wang F, et al. A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts. Mol Oncol. 2014 Dec;8(8):1640-52.

Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products

Product Promise

Promise
Molecular Weight (MW)392.49
Molecular FormulaC23H28N4O2
CAS No.315183-21-2
Storage-20℃ for 3 years in powder formrrrrrr
-80℃ for 2 years in solvent
Solubility In VitroDMSO: 78 mg/mL (198.73 mM)rrrrrr
Water:<1 mg/mL (slightly soluble or insoluble)rrrrrr
Ethanol: 16 mg/mL (40.76 mM)
Solubility In Vivo30% PEG400+0.5% Tween80+5% Propylene glycol: 30mg/mL
SMILES CodeO=C(N/N=C/C1=CC=CC(CC=C)=C1O)CN2CCN(CC3=CC=CC=C3)CC2
SynonymsPAC-1; PAC1; PAC 1; VO-100; VO100; VO 100; procaspase activating compound-1
ProtocolIn VitroPAC-1 activates procaspase-3 with an EC50 of 2.08 μM. PAC-1 exhibits an enhanced zinc chelating ability (EC50= 7.08 μM). PAC-1 induces leukemia cell death with IC50 of 4.03 μM, which is consistent with the values reported by other investigators. PAC-1 treatment also results in death of other malignant cells in a concentration-dependent manner with IC50s ranging from 4.03 to 53.44μM. The overall mean IC50 in the fifteen malignant cell lines is 0.88 mM for WF-210 and 19.40 μM for PAC-1. In contrast, the sensitivity of the normal human cells (PBL, L-02, HUVEC and MCF 10A) to WF-210 is 2.6-fold lower (mean IC50=412.34 μM) than PAC-1 (mean IC50=158.29 μM).
In VivoAs shown in both PAC-1 and WF-210 significantly inhibits the growth of Hep3B tumor xenografts.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM2.5478 mL12.7392 mL25.4784 mL50.9567 mL
5mM0.5096 mL2.5478 mL5.0957 mL10.1913 mL
10mM0.2548 mL1.2739 mL2.5478 mL5.0957 mL
20mM0.1274 mL0.6370 mL1.2739 mL2.5478 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O

Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.